Literature DB >> 2077344

Dissociation between Limulus neutralisation and in vivo protection in monoclonal antibodies directed against endotoxin core structures.

J S McConnell1, B J Appelmelk, J Cohen.   

Abstract

Studies with rough mutants of certain Gram-negative bacteria have indicated that monoclonal antibodies (mAbs) to endotoxin core can protect animals and man from endotoxic shock. We assessed the ability of such antibodies to neutralise endotoxin in the Limulus amoebocyte lysate (LAL) assay, and compared this to their protective effect in a murine model of endotoxic shock. We evaluated 11 mAbs raised against Salmonella minnesota R595. Endotoxin neutralisation in the LAL assay, expressed as 50% inhibition titres, ranged between 1/32 and 1/414. However, there was no apparent relationship between the titre required to produce 50% inhibition of LAL and its ability to protect mice from endotoxic shock. We conclude that LAL neutralisation appears unrelated to biological activity; in this system, LAL inhibition by mAb ascites cannot be used to predict protection in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2077344     DOI: 10.1016/0882-4010(90)90040-w

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  3 in total

1.  Change in plasma endotoxin titres and endotoxin neutralizing activity in the perioperative period.

Authors:  T Imai; T Shiga; N Saruki; K Nishikawa; T Fujita; Y Morishita
Journal:  Can J Anaesth       Date:  1996-08       Impact factor: 5.063

2.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

Review 3.  Endotoxemia: methods of detection and clinical correlates.

Authors:  J C Hurley
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.